Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients

(2015) Carmel Jacobs et al.   SUPPORTIVE CARE IN CANCER

Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review

(2015) Ricardo Fernandes et al.   SUPPORTIVE CARE IN CANCER

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

(2014) J. Baselga et al.   ANNALS OF ONCOLOGY

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†

(2014) A. M. Gonzalez-Angulo et al.   ANNALS OF ONCOLOGY

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

(2014) George Fountzilas et al.   BMC CANCER

North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study

(2014) Alexis D. Leal et al.   CANCER

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

(2014) Sandro Pignata et al.   LANCET ONCOLOGY

Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects

(2014) K. Beusterien et al.   ONCOLOGIST

Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

(2014) Sandra M. Swain et al.   ONCOLOGIST

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

(2013) A. Bahl et al.   ANNALS OF ONCOLOGY

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

(2013) Yong Wha Moon et al.   BMC CANCER

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

(2013) Hans-Joachim Lück et al.   BREAST CANCER RESEARCH AND TREATMENT

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

(2013) I. Kuchuk et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer

(2013) Andrew D. Seidman et al.   Clinical Breast Cancer

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

(2013) Helena M Earl et al.   LANCET ONCOLOGY

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of  III-Tubulin Expression as a Predictive Marker

(2013) C. Saura et al.   ONCOLOGIST

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

(2013) F. J. Esteva et al.   ONCOLOGIST

Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer

(2012) Alexandra Schönherr et al.   Breast Care

251 Retrospective Analysis of the Relative Efficacy and Toxicity of Nab-paclitaxel and Docetaxel in Metastatic Breast Cancer

(2012) S.J. Howell et al.   EUROPEAN JOURNAL OF CANCER

Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases

(2012) SangUk Woo et al.   Journal of Cancer Research and Therapeutics

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer

(2012) E. A. Wist et al.   Journal of Oncology

TAXTOX – a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009

(2011) Lise Eckhoff et al.   ACTA ONCOLOGICA

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel

(2011) Eva J Kantelhardt et al.   BMC CANCER

International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases

(2011) Edward Chow et al.   CANCER

Phase II Multicenter Trial of Albumin-Bound Paclitaxel and Capecitabine in First-Line Treatment of Patients With Metastatic Breast Cancer

(2011) Lee S. Schwartzberg et al.   Clinical Breast Cancer

5002 ORAL Complications Associated With Chemotherapy in Patients With Metastatic Breast Cancer

(2011) M. Brammer et al.   EUROPEAN JOURNAL OF CANCER

Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast

(2011) DhanyaS Palappallil et al.   INDIAN JOURNAL OF CANCER

Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer

(2011) R. Charles Coombes et al.   JOURNAL OF CLINICAL ONCOLOGY

Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1

(2011) Charles L. Loprinzi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Breast Cancer: BCIRG-005 Trial

(2011) Wolfgang Eiermann et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer

(2011) Carol M. Moinpour et al.   QUALITY OF LIFE RESEARCH

Phase II Trial of Dose Dense Docetaxel Followed by FEC100 as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer

(2010) William Jacot et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

(2010) N. Hatam et al.   ARCHIVES OF GYNECOLOGY AND OBSTETRICS

Regional and seasonal influence in patient’s toxicity to adjuvant chemotherapy for early breast cancer

(2010) Juan de la Haba-Rodríguez et al.   BREAST CANCER RESEARCH AND TREATMENT

A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer

(2010) Stacy L. Moulder et al.   CANCER

Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey

(2010) S. Saibil et al.   Current Oncology

552 CYP3A5*3 (rs776746) is associated with docetaxel-specific toxicities during adjuvant breast cancer chemotherapy

(2010) S. Damaraju et al.   EJC SUPPLEMENTS

361 Long-term cause specific mortality in patients treated for DCIS; a population based study

(2010) N. Boekel et al.   EJC SUPPLEMENTS

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

An evidence-based practice guideline for the peer review of electronic search strategies

(2009) Margaret Sampson et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY